The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes-Reference-Cited by-同舟云学术

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes

Published:2022-02-14 Issue:4 Volume:130 Page:513-521
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharma Tox

Author:

Björn Niclas¹^ORCID,Jakobsen Ingrid¹²^ORCID,Udagawa Chihiro³^ORCID,Brandén Eva⁴⁵,Koyi Hirsh⁴⁵,Lewensohn Rolf⁶⁷,De Petris Luigi⁶⁷,Zembutsu Hitoshi⁸^ORCID,Gréen Henrik¹⁹^ORCID

Affiliation:

1. Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden

2. Department of Laboratory Medicine Örebro University Hospital Örebro Sweden

3. Department of Genetic Medicine and Services National Cancer Center Hospital Tokyo Japan

4. Department of Respiratory Medicine Gävle Hospital Gävle Sweden

5. Centre for Research and Development Uppsala University/Region Gävleborg Gävle Sweden

6. Thoracic Oncology Unit, Tema Cancer Karolinska University Hospital Stockholm Sweden

7. Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden

8. Department of Clinical Genomics National Cancer Center Research Institute Tokyo Japan

9. Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Linköping Sweden

Funder

Linköpings Universitet

Vetenskapsrådet

Cancerfonden

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13712

Reference21 articles.

1. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

2. Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group

3. Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group